Bernard Chevalier

Showing 1-20 of 39 articles

Coronary interventions

Optimal Dual Antiplatelet Therapy Duration for Bioresorbable Scaffolds: an Individual Patient Data Pooled Analysis of the ABSORB Trials

Azzalini L, Ellis SG, Kereiakes D, Kimura T, Gao R, Onuma Y, Chevalier B, Dressler O, Crowley A, Zhou Z, Redfors B, Serruys P, Stone G

June 8, 2021 | 10.4244/EIJ-D-21-00263

Coronary interventions

Clinical Outcomes of Proximal Optimization Technique (POT) in Bifurcation Stenting

Chevalier B, Mamas M, Hovasse T, Rashid M, Gomez JA, Pan M, Witkowski A, Crowley J, Aminian A, McDonald J, Beygui F, Portales J, Roguin A, Stankovic G

May 11, 2021 | 10.4244/EIJ-D-20-01393

Coronary interventions

Proximal Optimisation Technique Versus Final Kissing Balloon Inflation in Coronary Bifurcation Lesions: the Randomised, Multicenter PROPOT Trial

Watanabe Y, Murasato Y, Yamawaki M, Kinoshita Y, Okubo M, Yumoto K, Masuda N, Otake H, Aoki J, Nakazawa G, Numasawa Y, Ito T, Shite J, Okamura T, Takagi K, Kozuma K, Lefèvre T, Chevalier B, Louvard Y, Suzuki N, Kozuma K

March 30, 2021 | 10.4244/EIJ-D-20-01386

Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial

Onuma Y, Chevalier B, Ono M, Cequier A, Dudek D, Haude M, Carrié D, Sabaté M, Windecker S, Rapoza R, West N, Reith S, de Sousa Almeida M, Campo G, Iniguez-Romo A, Serruys P

December 4, 2020 | 10.4244/EIJ-D-20-00024

Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trial

Smits P, Chang C, Chevalier B, West N, Gori T, Barbato E, Tarantini G, Kocka V, Achenbach S, Dudek D, Escaned J, Wlodarczak A, Abdel-Wahab M, Esposito G, Tijssen J, Morice M, Onuma Y, van Geuns R

October 23, 2020 | 10.4244/EIJ-D-19-01079

Impact of coronary lesion complexity in percutaneous coronary intervention: one-year outcomes from the large, multicentre e-Ultimaster registry

Mohamed M, Polad J, Hildick-Smith D, Bizeau O, Baisebenov R, Roffi M, Iniguez-Romo A, Chevalier B, von Birgelen C, Roguin A, Aminian A, Angioi M, Mamas M

September 18, 2020 | 10.4244/EIJ-D-20-00361

Coronary interventions

Acute and long-term relocation of minimal lumen area after bioresorbable scaffold or metallic stent implantation

Katagiri Y, Serruys P, Tenekecioglu E, Asano T, Collet C, Miyazaki Y, Katsikis A, Piek J, Wykrzykowska J, Chevalier B, Mintz G, Stone G, Onuma Y

September 20, 2019 | 10.4244/EIJ-D-18-00422

Coronary interventions

Relation between bioresorbable scaffold sizing using QCA-Dmax and long-term clinical outcomes in 1,232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II)

Katagiri Y, Onuma Y, Asano T, Chichareon P, Collet C, Miyazaki Y, Piek J, Wykrzykowska J, Abizaid A, Ormiston J, Chevalier B, Serruys P

October 12, 2018 | 10.4244/EIJ-D-18-00301

Polymer-free drug-coated stents: workhorse or “niche horse”?

Urban P, Chevalier B

September 20, 2018 | 10.4244/EIJV14I7A128

Stents and scaffolds

Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

Chevalier B, Cequier A, Dudek D, Haude M, Carrié D, Sabaté M, Windecker S, Reith S, de Sousa Almeida M, Campo G, Iñiguez A, Onuma Y, Serruys P

January 19, 2018 | 10.4244/EIJ-D-17-00873

Coronary interventions

Does geographical variability influence five-year MACCE rates in the multicentre SYNTAX revascularisation trial?

Roy A, Chevalier B, Lefèvre T, Louvard Y, Segurado R, Sawaya F, Spaziano M, Neylon A, Serruys P, Dawkins K, Kappetein A, Mohr F, Colombo A, Feldman T, Morice M

September 20, 2017 | 10.4244/EIJ-D-16-00991

Coronary interventions

Chronic total coronary occlusion treated by percutaneous coronary intervention: long-term outcome in patients with and without diabetes

Sanguineti F, Garot P, O’Connor S, Watanabe Y, Spaziano M, Lefèvre T, Hovasse T, Benamer H, Unterseeh T, Chevalier B, Morice M, Louvard Y

February 3, 2017 | 10.4244/EIJ-D-15-00278

Coronary interventions

Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial

Chevalier B, Onuma Y, Van Boven A, Piek J, Sabaté M, Helqvist S, Baumbach A, Smits P, Kumar R, Wasungu L, Serruys P

October 20, 2016 | 10.4244/EIJY16M08_01

Interventions for valvular disease

Patient-specific image-based computer simulation for the prediction of valve morphology and calcium displacement after TAVI with the Medtronic CoreValve and the Edwards SAPIEN valve

Schultz C, Rodriguez-Olivares R, Bosmans J, Lefèvre T, De Santis G, Bruining N, Collas V, Dezutter T, Bosmans B, Rahhab Z, Faquir N, Watanabe Y, Segers P, Verhegghe B, Chevalier B, Van Mieghem N, De Beule M, Mortier P, de Jaegere P

January 20, 2016 | 10.4244/EIJV11I9A212

Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data

Bourantas C, Serruys P, Nakatani S, Zhang Y-J, Farooq V, Diletti R, Ligthart J, Sheehy A, van Geuns R, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Rapoza R, Veldhof S, Onuma Y, Garcia-Garcia H

November 20, 2015 | 10.4244/EIJY14M10_06

Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial

Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P

September 22, 2015 | 10.4244/EIJY14M12_13

Impact of post-dilation on the acute and one-year clinical outcomes of a large cohort of patients treated solely with the Absorb Bioresorbable Vascular Scaffold

Costa Jr J, Abizaid A, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Perin M, Seth A, Botelho R, Serruys P

June 19, 2015 | 10.4244/EIJY15M05_06

Coronary interventions

The future of BRS in bifurcations

Kraak R, Grundeken M.J, Onuma Y, Tu S, Wykrzykowska J, Chevalier B, Ormiston J, Serruys P

May 19, 2015 | 10.4244/EIJV11SVA45

The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled

Abizaid A, Costa Jr J, Bartorelli A, Whitbourn R, van Geuns R, Chevalier B, Patel T, Seth A, Stuteville M, Dorange C, Cheong W-F, Sudhir K, Serruys P

April 20, 2015 | 10.4244/EIJV10I12A243

Circumferential distribution of the neointima at six-month and two-year follow-up after a bioresorbable vascular scaffold implantation: a substudy of the ABSORB Cohort B Clinical Trial

Bourantas C, Farooq V, Zhang Y-J, Muramatsu T, Gogas B, Thuesen L, McClean D, Chevalier B, Windecker S, Koolen J, Ormiston J, Whitbourn R, Dorange C, Rapoza R, Onuma Y, Garcia-Garcia H, Serruys P

March 20, 2015 | 10.4244/EIJY14M04_11

Latest news

NEW ISSUE

Robotics, AI and Imaging State of The Art; Bleeding Risk and Mortality in CAD; Treating Refractory Angina by Coronary Sinus Narrowing; and more

September 20, 2021

STATE OF THE ART

Robotics, imaging, and artificial intelligence in the catheterisation laboratory

Rafael Beyar et al.

September 20, 2021

AHEAD OF PRINT

ViV TAVI vs repeat SAVR

Monil Majmundar et al.

September 15, 2021

AHEAD OF PRINT

Thrombectomy for ischaemic stroke

Christopher A. Rajkumar et al.

September 10, 2021

EDITORIAL

Walking the tightrope between ischaemia and bleeding

Michelle L. O’Donoghue et al.

September 20, 2021

EDITORIAL

Microvascular dysfunction endotypes and outcomes

Christos V. Bourantas et al.

September 20, 2021

EDITORIAL

Coronary sinus reducer therapy for refractory angina: is it ready for prime time?